

-2-

3. (Amended) A method according to claim 2, [further comprises] wherein the antibody is administered in a pharmaceutical carrier.
8. (Amended) A method according to claim 7, wherein said anti-TNF antibody is [selected from A2 and] CA2.
21. (Amended) A method according to claim 17, wherein said [the] heavy chain further comprises a variable region capable of binding to a second target molecule.
22. (Amended) A method according to claim 17, wherein said [the] heavy chain is an IgG class heavy chain.
23. (Amended) A method according to claim 16, wherein said [the] non-immunoglobulin molecule comprises at least a portion of p55.
24. (Amended) A method according to claim 23, wherein the non-immunoglobulin molecule comprises sequences within 2-159 of p55.
25. (Amended) A method according to claim [24] 23, wherein the non-immunoglobulin molecule comprises sequences within 1-235 of p75.
26. (Amended) A method according to claim 25, wherein said non-immunoglobulin molecule comprises sequences within 1-182 of p75.
27. (Amended) A method according to claim 26, wherein the non-immunoglobulin molecule comprises sequences within 1-178 of p75.

-3-

B4 35. (Amended) A method according to claim [17] 33, wherein said immunoreceptor molecule is capable of neutralizing TNF wherein a concentration of less than about 130 pM is capable of neutralizing about 39.2 pM human TNF α .

B5 42. (Amended) A method according to claim 1, wherein said pathology is selected from the group consisting of [a chronic] an inflammatory pathology, an autoimmune disease, an infection, a neurodegenerative disease, and a malignant pathology.

B6 50. (Amended) A method according to claim [43] 49 wherein said vascular inflammatory pathology is selected from the group consisting of disseminated intravascular coagulation, atherosclerosis and Kawasaki's pathology.

B7 56. (Amended) A method according to claim 55, wherein said infection is selected from the group consisting of sepsis syndrome, cachexia, a bacterial infection, circulatory collapse and shock resulting from a bacterial infection, a viral infection, [and] or a fungal infection.

B8 70. (Amended) A method according to claim [69] 67 wherein said tumor is a TNF secreting tumor.

B9 73. (Amended) A method according to claim [68] 67 wherein said pathology is a lymphoma.

74. (Amended) A method according to claim 73, wherein said lymphoma is selected from the group consisting of acute lymphoma, chronic myelocytic lymphoma, chronic lymphocytic and/or myelodysplastic syndrome.

77. (Amended) A method according to claim 76, wherein said fragment comprises sequences within 2-159 of p55.